Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyAmeriHealth Caritas Dermabrasion Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentAmeriHealth CaritasPolicy CCP.1323

    Dermabrasion and chemical peel

    Customize your policy alerts

    Sign up for AmeriHealth Caritas Policy CCP.1323 alerts

    Get alerted when Policy CCP.1323 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage determinations for dermabrasion, ablative skin resurfacing, and chemical peels, primarily as field treatment for extensive or diffuse actinic keratoses; cosmetic and other uses are not medically necessary.

    Policy Summary
    PayerAmeriHealth Caritas
    PolicyDermabrasion and chemical peel
    Policy CodePolicy CCP.1323
    Change TypeReference updates only
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateDec 1, 2027
    Key ActionUse field-directed resurfacing or trichloroacetic acid peels only for extensive or diffuse actinic keratoses when conventional methods are ineffective, contraindicated, or refused.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered field-treatment modalities
    3Chemical peel depth levels

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    53
    Field-resurfacing studies
    13Listed CPT codes

    Medical Necessity and Noncovered Uses

    Ablative resurfacing or dermabrasion for actinic keratosis

    Ablative skin resurfacing, including laser resurfacing or dermabrasion, may be medically necessary when all of the following are met.

    Ablative resurfacing for actinic keratoses

    • ALL of the following

      • The service is used as field treatment for extensive or diffuse precancerous actinic keratoses.
      • At least one applies

        • Conventional methods are not effective because of the large number of lesions.
        • Conventional methods are contraindicated.
        • The patient refuses conventional methods.

    Trichloroacetic acid chemical peel for actinic keratosis

    Trichloroacetic acid chemical peels may be medically necessary when all of the following are met.

    Trichloroacetic acid peel for actinic keratoses

    • ALL of the following

      • The service is used as field treatment for extensive or diffuse precancerous actinic keratoses.
      • At least one applies

        • Conventional methods are not effective because of the large number of lesions.
        • Conventional methods are contraindicated.
        • The patient refuses conventional methods.

    Cosmetic uses and other uses of dermabrasion or chemical peels are excluded because they are considered investigational or not clinically proven.

    Dermabrasion and chemical peels are contraindicated in the presence of an active bacterial, viral, or fungal infection, active acne, a tendency to form keloids, facial dermatitis, current use of photosensitizing medications, previous radiation treatment, or unrealistic patient expectations.

    Field-directed dermabrasion, ablative resurfacing, and trichloroacetic acid peels are intended for field cancerization or confluent epidermal dysplasia, such as extensive or diffuse actinic keratoses. They should not be interpreted as treatment for a discrete invasive squamous cell carcinoma or other discrete invasive carcinoma; surgical excision remains the primary treatment for basal cell carcinoma and cutaneous squamous cell carcinoma.

    Other uses of dermabrasion and chemical peels, including cosmetic purposes, are considered investigational or not clinically proven and therefore are not medically necessary.

    Related Procedure Codes

    Related CPT CodesCPT
    15780Dermabrasion, total face
    15781Dermabrasion, segmental face
    15782Dermabrasion, regional, other than face
    15783Dermabrasion, superficial, any site
    15786Abrasion, single lesion (e.g., keratosis or scar)
    15787Abrasion, each additional four lesions or fewer; add-on code
    15788Chemical peel, facial; epidermal
    15789Chemical peel, facial; dermal
    15792Chemical peel, nonfacial; epidermal
    15793Chemical peel, nonfacial; dermal
    1–10 of 11
    1/2

    Coverage and Treatment Warnings

    Denial Risk

    Cosmetic or Other Noncovered Use

    Do not consider dermabrasion or chemical peels medically necessary when performed for cosmetic purposes or for uses outside covered treatment of actinic keratosis. These uses are considered investigational/not clinically proven.

    Denial Risk

    Contraindications

    Do not perform dermabrasion or chemical peels when contraindications are present, including active infection, active acne, keloid tendency, facial dermatitis, photosensitizing medication use, prior radiation treatment, or unrealistic expectations.

    • Active bacterial, viral, or fungal infection
    • Active stages of acne
    • Tendency to keloid formation
    • Facial dermatitis
    • Current use of photosensitizing medications
    • Previous radiation treatments
    • Unrealistic expectations

    Procedural Background

    Dermabrasion mechanically removes the epidermis and superficial dermis, while ablative laser resurfacing removes the epidermis and controlled portions of the dermis. These procedures remodel the superficial skin layers and may be used as field treatment for extensive or diffuse actinic keratoses when conventional therapies are ineffective, contraindicated, or refused.

    Procedure and Clinical Definitions

    Dermabrasion
    ProcedureUses a hand-held, rapidly rotating wire brush or diamond fraise (steel wheel) to plane or sand facial skin.
    Tissue removedRemoves the epidermis and superficial dermis.
    Clinical distinctionTraditional dermabrasion is more invasive than microdermabrasion and has been used less often because less invasive procedures are available.
    Microdermabrasion
    Procedure typeA less invasive, nonsurgical exfoliation procedure.
    Skin layer addressedExfoliates or removes the top layer of skin, known as the stratum corneum.
    Delivery method
    Policy Summary
    PayerAmeriHealth Caritas
    PolicyDermabrasion and chemical peel
    Policy CodePolicy CCP.1323
    Change TypeReference updates only
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateDec 1, 2027
    Key ActionUse field-directed resurfacing or trichloroacetic acid peels only for extensive or diffuse actinic keratoses when conventional methods are ineffective, contraindicated, or refused.
    SourceLink
    On This Page
    Medical Necessity and Noncovered UsesRelated Procedure CodesCoverage and Treatment WarningsProcedural BackgroundProcedure and Clinical Definitions
    Denial Risk

    Not a Treatment for Invasive Carcinoma

    Do not use field-directed dermabrasion, ablative resurfacing, or trichloroacetic acid peels to treat discrete invasive squamous cell carcinoma or other invasive carcinoma. These modalities may be considered only in the context of actinic keratosis with field cancerization or confluent epidermal dysplasia; surgical excision remains the primary treatment for basal cell carcinoma and cutaneous squamous cell carcinoma.

    • Not a treatment for discrete invasive squamous cell carcinoma.
    • Not a treatment for other invasive carcinoma.
    • For basal cell carcinoma and cutaneous squamous cell carcinoma, clinical guidelines consistently recommend surgical excision as the primary treatment modality.
    Uses aluminum oxide crystals or another abrasive substance blown onto the face with a hand-held device.
    Chemical peel
    DefinitionA solution is applied to the skin, causing exfoliation and eventual peeling.
    Superficial peelGently exfoliates the outer layer of skin and typically takes one to seven days to heal.
    Medium peelUses glycolic or trichloroacetic acid to remove damaged cells in the outer and middle skin layers; healing typically takes seven to 14 days.
    Deep peelUses trichloroacetic acid or phenol to penetrate the middle skin layer and remove damaged cells; healing typically takes 14 to 21 days.
    Field cancerization or confluent epidermal dysplasia
    DefinitionA field of extensive or confluent precancerous epidermal change, such as extensive or diffuse actinic keratoses.
    Treatment contextField-directed treatment may include trichloroacetic acid peels and ablative resurfacing techniques, including dermabrasion and laser treatments.
    Clinical boundaryField-directed modalities should not be interpreted as treatment for a discrete invasive squamous cell carcinoma or other discrete invasive carcinoma.